03/04/2024 – AB Science today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseNextNext post:AB Science announces a slight delay in the publication of its 2023 annual financial reportRelated PostsPositive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024June 26, 2024 CGM – Q&A documentJune 26, 2024Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024AB Science webcast of May 30, 2024May 30, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024
